Hanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares

Bulletin Express06-12 19:43

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a price range of HK$26.00–27.70, giving a volume-weighted average cost of HK$26.8349 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.031% to 134.92 million shares, while treasury holdings rose to 1.29 million shares. Total issued shares remained unchanged at 136.22 million.

The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.29 million shares, representing 0.95% of the share count on the mandate date.

Under Hong Kong listing rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026. The board confirmed that the repurchase was conducted in full compliance with all applicable regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151610282?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151610282","market":"us","top_or_hot":-1,"title":"Hanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a price range of HK$26.00–27.70, giving a volume-weighted average cost of HK$26.8349 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.031% to 134.92 million shares, while treasury holdings rose to 1.29 million shares. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.29 million shares, representing 0.95% of the share count on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026. The board confirmed that the repurchase was conducted in full compliance with all applicable regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharmaceuticals executes HK$1.12 million H-share repurchase, increasing treasury stock to 1.29 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-12 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a price range of HK$26.00–27.70, giving a volume-weighted average cost of HK$26.8349 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.031% to 134.92 million shares, while treasury holdings rose to 1.29 million shares. Total issued shares remained unchanged at 136.22 million.</p>\n<p>The buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.29 million shares, representing 0.95% of the share count on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026. The board confirmed that the repurchase was conducted in full compliance with all applicable regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1151610282","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151610282","pubTimestamp":1781264615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药执行112万港元H股回购库存股增至129万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that on 12 June 2026 it repurchased 41,800 H shares on the Hong Kong Stock Exchange, spending HK$1.12 million. The shares were acquired within a price range of HK$26.00–27.70, giving a volume-weighted average cost of HK$26.8349 per share.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.031% to 134.92 million shares, while treasury holdings rose to 1.29 million shares. Total issued shares remained unchanged at 136.22 million.\nThe buyback forms part of a mandate approved on 12 February 2026 that authorises repurchases of up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 1.29 million shares, representing 0.95% of the share count on the mandate date.\nUnder Hong Kong listing rules, Hanx Biopharmaceuticals is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 July 2026. The board confirmed that the repurchase was conducted in full compliance with all applicable regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151610282","isCrawlerRequest":true}